U.S. Pharmaceuticals & Biotech Healthy high growth potential

Axsome Therapeutics

Market Cap: US$10.9b

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

TG Therapeutics

Market Cap: US$7.1b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Madrigal Pharmaceuticals

Market Cap: US$11.8b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

Insmed

Market Cap: US$28.6b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Praxis Precision Medicines

Market Cap: US$10.1b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Marker Therapeutics

Market Cap: US$18.7m

A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.

AnaptysBio

Market Cap: US$1.7b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Ardelyx

Market Cap: US$996.8m

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Ionis Pharmaceuticals

Market Cap: US$9.4b

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

Alnylam Pharmaceuticals

Market Cap: US$29.3b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Adaptive Biotechnologies

Market Cap: US$4.0b

A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

Aldeyra Therapeutics

Market Cap: US$93.5m

A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.

Revolution Medicines

Market Cap: US$44.0b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

Tenaya Therapeutics

Market Cap: US$157.7m

A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Capricor Therapeutics

Market Cap: US$236.9m

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Forum Markets

Market Cap: US$79.5m

A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.

INmune Bio

Market Cap: US$55.4m

A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

Corcept Therapeutics

Market Cap: US$12.0b

A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

RenovoRx

Market Cap: US$50.5m

A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Lineage Cell Therapeutics

Market Cap: US$274.2m

A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

Achieve Life Sciences

Market Cap: US$682.7m

A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

Zevra Therapeutics

Market Cap: US$686.5m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

Citius Oncology

Market Cap: US$70.7m

Focuses on the development and commercialization of targeted oncology therapies.

Longeveron

Market Cap: US$24.4m

A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.

Hyperion DeFi

Market Cap: US$40.5m

A DeFi company, engages in building on Hyperliquid.

CG Oncology

Market Cap: US$6.7b

A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

Nuvation Bio

Market Cap: US$2.3b

A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

BioStem Technologies

Market Cap: US$72.6m

Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Eton Pharmaceuticals

Market Cap: US$1.2b

A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

Humacyte

Market Cap: US$193.7m

Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Kiniksa Pharmaceuticals International

Market Cap: US$5.9b

A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.

Viridian Therapeutics

Market Cap: US$2.7b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Arcutis Biotherapeutics

Market Cap: US$3.2b

A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Codexis

Market Cap: US$158.1m

Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.

Larimar Therapeutics

Market Cap: US$434.2m

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Belite Bio

Market Cap: US$6.4b

A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.